{"id":"traditional-cryoprecipitate","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Thromboembolic events"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cryoprecipitate is prepared by thawing fresh frozen plasma at cold temperatures, causing fibrinogen, fibronectin, von Willebrand factor, factor VIII, and factor XIII to precipitate out. When transfused, these concentrated clotting factors restore the patient's ability to form stable blood clots and control bleeding. It is used primarily in acute bleeding situations where rapid fibrinogen replacement is needed.","oneSentence":"Cryoprecipitate is a blood product concentrate that replaces deficient clotting factors and fibrinogen to restore hemostatic function in patients with bleeding disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:24.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fibrinogen deficiency or dysfibrinogenemia with active bleeding"},{"name":"Factor VIII deficiency (hemophilia A) when specific factor concentrates unavailable"},{"name":"von Willebrand disease with severe bleeding"},{"name":"Disseminated intravascular coagulation (DIC) with fibrinogen depletion"},{"name":"Massive transfusion protocols for acute hemorrhage"}]},"trialDetails":[{"nctId":"NCT07484087","phase":"NA","title":"Ablation Compare With Surgery for Early Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Breast Cancer, Early Stage, Hormone Receptor Positive","enrollment":264},{"nctId":"NCT05095909","phase":"NA","title":"Utility of Intermittent Cryo-Compression Versus Traditional Icing Following Arthroscopic Rotator Cuff Repair","status":"RECRUITING","sponsor":"Allina Health System","startDate":"2024-08-05","conditions":"Rotator Cuff Injuries, Cryotherapy Effect","enrollment":100},{"nctId":"NCT05711524","phase":"PHASE4","title":"Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-04-01","conditions":"Hypofibrinogenemia, Bleeding","enrollment":208},{"nctId":"NCT04548830","phase":"PHASE2","title":"Safety of Lung Cryobiopsy in People With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-08","conditions":"Lung Cancer","enrollment":100},{"nctId":"NCT06795269","phase":"NA","title":"EFFECT OF CRYOTHERAPY ON KINEMATIC GAIT PARAMETERS IN PATIENTS WITH CHRONIC PATELLOFEMORAL PAIN SYNDROME","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-10-08","conditions":"CHRONIC PATELLOFEMORAL PAIN SYNDROME","enrollment":60},{"nctId":"NCT04334785","phase":"NA","title":"Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer","enrollment":186},{"nctId":"NCT01298986","phase":"EARLY_PHASE1","title":"Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2011-05","conditions":"Ablation of Atrial Fibrillation","enrollment":""},{"nctId":"NCT01223105","phase":"PHASE2, PHASE3","title":"Oocyte Cryopreservation by Slow Freezing and Vitrification","status":"TERMINATED","sponsor":"Reproductive Medicine Associates of New Jersey","startDate":"2009-07","conditions":"Women Diagnosed With Cancer, Egg Donors, Single Women","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Traditional Cryoprecipitate","genericName":"Traditional Cryoprecipitate","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cryoprecipitate is a blood product concentrate that replaces deficient clotting factors and fibrinogen to restore hemostatic function in patients with bleeding disorders. Used for Fibrinogen deficiency or dysfibrinogenemia with active bleeding, Factor VIII deficiency (hemophilia A) when specific factor concentrates unavailable, von Willebrand disease with severe bleeding.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}